Stralem & Co’s Biogen BIIB Stock Holding History

Stralem & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$27K	Hold	101	–	–	0.02%	60
2020 Q1	$32K	Buy	+101	New	+$30.7K	0.02%	55

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stralem & Co's BIIB Position: Q2 2020 in Review

Stralem & Co held its Biogen (BIIB) position steady in Q2 2020 at 101 shares worth $27K. The position accounts for 0.02% of the portfolio, ranked #60.

Stralem & Co first reported a position in BIIB in Q1 2020 and has held it in 2 quarters since. The position peaked at $32K in Q1 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Stralem & Co held 101 shares of Biogen worth $27K as of Q2 2020.
Stralem & Co left its Biogen share count unchanged in Q2 2020.
Biogen made up 0.02% of Stralem & Co's portfolio in Q2 2020, its #60 holding.
Stralem & Co first reported a position in Biogen in Q1 2020 and has held it in 2 quarters since.
Stralem & Co's Biogen position peaked at $32K in Q1 2020.
1,060 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.